Literature DB >> 20659297

Cannabinoid agonist WIN55,212 in vitro inhibits interleukin-6 (IL-6) and monocyte chemo-attractant protein-1 (MCP-1) release by rat pancreatic acini and in vivo induces dual effects on the course of acute pancreatitis.

C Petrella1, S Agostini, G S Alema', P Casolini, F Carpino, C Giuli, G Improta, G Linari, V Petrozza, M Broccardo.   

Abstract

BACKGROUND: Cannabinoids (CBs) evoke their effects by activating the cannabinoid receptor subtypes CB1-r and CB2-r and exert anti-inflammatory effects altering chemokine and cytokine expression. Various cytokines and chemokines are produced and released by rodent pancreatic acini in acute pancreatitis. Although CB1-r and CB2-r expressed in rat exocrine pancreatic acinar cells do not modulate digestive enzyme release, whether they modulate inflammatory mediators remains unclear. We investigated the CB-r system role on exocrine pancreas in unstimulated conditions and during acute pancreatitis.
METHODS: We evaluated in vitro and in vivo changes induced by WIN55,212 on the inflammatory variables amylasemia, pancreatic edema and morphology, and on acinar release and content of the cytokine interleukin-6 (IL-6) and chemokine monocyte chemo-attractant protein-1 (MCP-1) in untreated rats and rats with caerulein (CK)-induced pancreatitis. KEY
RESULTS: In the in vitro experiments, WIN55,212 (10(-6) mol L(-1)) inhibited IL-6 and MCP-1 release from acinar cells of unstimulated rats and after CK-induced pancreatitis. In vivo, when rats were pretreated with WIN55,212 (2 mg kg(-1), intraperitoneally) before experimentally-induced pancreatitis, serum amylase, pancreatic edema and IL-6 and MCP-1 acinar content diminished and pancreatic morphology improved. Conversely, when rats with experimentally-induced pancreatitis were post-treated with WIN55,212, pancreatitis worsened. CONCLUSIONS & INFERENCES: These findings provide new evidence showing that the pancreatic CB1-r/CB2-r system modulates pro-inflammatory factor levels in rat exocrine pancreatic acinar cells. The dual, time-dependent WIN55,212-induced changes in the development and course of acute pancreatitis support the idea that the role of the endogenous CB receptor system differs according to the local inflammatory status.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20659297     DOI: 10.1111/j.1365-2982.2010.01569.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  7 in total

1.  Severity and outcomes of acute alcoholic pancreatitis in cannabis users.

Authors:  Hemant Goyal; Kelsey Guerreso; Betsy Smith; Kaitlin Harper; Sheetal Patel; Akash Patel; Puja Parikh
Journal:  Transl Gastroenterol Hepatol       Date:  2017-07-21

Review 2.  Is lipid signaling through cannabinoid 2 receptors part of a protective system?

Authors:  P Pacher; R Mechoulam
Journal:  Prog Lipid Res       Date:  2011-02-02       Impact factor: 16.195

Review 3.  Modulating the endocannabinoid system in human health and disease--successes and failures.

Authors:  Pál Pacher; George Kunos
Journal:  FEBS J       Date:  2013-04-22       Impact factor: 5.542

4.  Src kinases play a novel dual role in acute pancreatitis affecting severity but no role in stimulated enzyme secretion.

Authors:  Bernardo Nuche-Berenguer; Irene Ramos-Álvarez; R T Jensen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-03-31       Impact factor: 4.052

5.  Anti-inflammatory effect of cannabinoid agonist WIN55, 212 on mouse experimental colitis is related to inhibition of p38MAPK.

Authors:  Ya-Jing Feng; Yong-Yu Li; Xu-Hong Lin; Kun Li; Ming-Hua Cao
Journal:  World J Gastroenterol       Date:  2016-11-21       Impact factor: 5.742

6.  The Impact of CB1 Receptor on Inflammation in Skeletal Muscle Cells.

Authors:  Mansour Haddad
Journal:  J Inflamm Res       Date:  2021-08-14

7.  Effect of Monoacylglycerol Lipase Inhibition on Intestinal Permeability of Rats With Severe Acute Pancreatitis.

Authors:  Jing Wang; Hongwei Xu; Tianjie Chen; Changqin Xu; Xiaohua Zhang; Shule Zhao
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.